Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax Provisions
Others
Ratios

Centessa Pharmaceuticals (CNTA) Net Income towards Common Stockholders: 2019-2024

Historic Net Income towards Common Stockholders for Centessa Pharmaceuticals (CNTA) over the last 6 years, with Dec 2024 value amounting to -$235.8 million.

  • Centessa Pharmaceuticals' Net Income towards Common Stockholders fell 28.96% to -$54.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$242.7 million, marking a year-over-year decrease of 50.50%. This contributed to the annual value of -$235.8 million for FY2024, which is 56.04% down from last year.
  • Per Centessa Pharmaceuticals' latest filing, its Net Income towards Common Stockholders stood at -$235.8 million for FY2024, which was down 56.04% from -$151.1 million recorded in FY2023.
  • In the past 5 years, Centessa Pharmaceuticals' Net Income towards Common Stockholders registered a high of -$10.7 million during FY2020, and its lowest value of -$381.1 million during FY2021.
  • In the last 3 years, Centessa Pharmaceuticals' Net Income towards Common Stockholders had a median value of -$216.2 million in 2022 and averaged -$201.0 million.
  • Its Net Income towards Common Stockholders has fluctuated over the past 5 years, first tumbled by 3,473.77% in 2021, then spiked by 43.26% in 2022.
  • Over the past 5 years, Centessa Pharmaceuticals' Net Income towards Common Stockholders (Yearly) stood at -$10.7 million in 2020, then crashed by 3,473.77% to -$381.1 million in 2021, then soared by 43.26% to -$216.2 million in 2022, then surged by 30.12% to -$151.1 million in 2023, then plummeted by 56.04% to -$235.8 million in 2024.